Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Durect Corp. (NASDAQ: DRRX).

Full DD Report for DRRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: DRRX)

Your Daily Pharma Scoop: AcelRx Resubmits, MannKind Finds New Realms, VTVT Up On Mixed Data
Analysis focus: ACRX If you recall your AcelRx (NASDAQ: ACRX ), it got a CRL for DSUVIA lasy year citing safety concerns and drug administration issues. The exact things the FDA said, as reported by the company, were: “The two primary recommendations within the CRL are: first, while...
Source: SeekingAlpha
Date: May, 10 2018 10:00
DURECT up 8% premarket on revised Posimir contract with Sandoz
DURECT (NASDAQ: DRRX ) is up  8%  premarket, albeit on only 1,100 shares, on the heels of its announcement that it has amended its POSIMIR (SABER-bupivacaine) agreement with Novartis' (NYSE: NVS ) Sandoz unit. More news on: Durect Corporation, Novartis AG, Healthcare stocks new...
Source: SeekingAlpha
Date: May, 09 2018 09:05
DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR® (SABER®-Bupivacaine)
CUPERTINO, Calif. , May 9, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has entered into an amendment (the "Amendment") to the development and commercialization agreement with Sandoz AG, a division of Novartis (NYSE: NVS), regarding POSIMIR ® (SABER...
Source: PR Newswire
Date: May, 09 2018 08:00
DURECT's (DRRX) CEO James Brown on Q1 2018 Results - Earnings Call Transcript
Start Time: 16:30 End Time: 17:03 DURECT Corporation (DRRX) Q1 2018 Earnings Conference Call May 02, 2018, 16:30 PM ET Executives James Brown - President and CEO Matthew Hogan - CFO WeiQi Lin - SVP, R&D, R&D Business Development and Principal Scientist Analysts ...
Source: SeekingAlpha
Date: May, 02 2018 21:12
DURECT Corporation Announces First Quarter 2018 Financial Results and Provides Corporate Update
CUPERTINO, Calif. , May 2, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2018 and provided a corporate update.   Total revenues were $3.5 million and net loss was $8.3 million for the three...
Source: PR Newswire
Date: May, 02 2018 16:05
Cirius Therapeutics completes enrollment in mid-stage study of lead candidate in NASH
Privately held Cirius Therapeutics announces that it has reached the enrollment target in a Phase 2b clinical trial, EMMINENCE , assessing lead candidate MSDC-0602K in patients with NASH and liver fibrosis. More news on: Conatus Pharmaceuticals, Galectin Therapeutics, Inc., Navidea Bi...
Source: SeekingAlpha
Date: May, 02 2018 10:47
Opioid prescriptions dropped 12% in 2017
Opioid prescriptions dropped 12% in 2017, according to a report from the IQVIA Institute for Human Data Science. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Industries Limited, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: April, 26 2018 03:18
DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis
CUPERTINO, Calif. , April 25, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with alcoholic hepatitis (AH).  DUR-928, the lead investigational product in our Epigenetic Regulat...
Source: PR Newswire
Date: April, 25 2018 08:00
DURECT Corporation Invites You to Join its First Quarter 2018 Earnings Conference Call
CUPERTINO, Calif. , April 24, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's(Nasdaq: DRRX) first quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, May 2, 2018 at 4...
Source: PR Newswire
Date: April, 24 2018 16:30
U.S. opioid prescriptions down 12% last year, largest drop in 25 years
According to IQVIA ( IQV -0.8% ), U.S. opioid prescriptions declined 12% in 2017, the largest annual drop in 25 years as doctors respond to the opioid crisis. More news on: IQVIA Holdings, Inc., Insys Therapeutics, Inc., Johnson & Johnson, Healthcare stocks news, News on ETFs, ...
Source: SeekingAlpha
Date: April, 19 2018 11:25

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-06-212.061.9852.081.92621,496
2018-06-202.102.052.122.03366,326
2018-06-142.112.112.152.085498,267
2018-06-132.152.082.162.06524,129
2018-06-122.132.1352.18032.11451,795

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-06-2192,001295,40131.1444Cover
2018-06-2045,790180,03225.4344Cover
2018-06-1944,927212,40221.1519Cover
2018-06-1865,496424,00415.4470Cover
2018-06-1540,583266,66115.2189Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DRRX.


About Durect Corp. (NASDAQ: DRRX)

Logo for Durect Corp. (NASDAQ: DRRX)

Not available

 

Contact Information

 

 

Current Management

  • James E. Brown / President, CEO
  • Matthew Hogan / CFO

Current Share Structure

  • Market Cap: $268,339,698 - 05/11/2018
  • Issue and Outstanding: 153,336,970 - 03/02/2018

 


Recent Filings from (NASDAQ: DRRX)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 25 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: April, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 20 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 01 2018

 

 


Daily Technical Chart for (NASDAQ: DRRX)

Daily Technical Chart for (NASDAQ: DRRX)


Stay tuned for daily updates and more on (NASDAQ: DRRX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: DRRX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DRRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of DRRX and does not buy, sell, or trade any shares of DRRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/